DDX11 and hepatocellular carcinoma: A clinical study with a five-year following-up pointed out that patients who had high DDX11-AS1 expressions displayed a shorter OS and PFI, suggesting that overexpression of DDX11-AS1 may positively influence the clinical progression of HCC.